GLP-1 vs Metformin in Prediabetes: 256,492-Patient Data Reshape Peptide Therapy Debate
A retrospective analysis of 256,492 U.S. adults with prediabetes and obesity found that users of GLP-1 receptor agonists had a 31% lower risk of progressing to type 2 diabetes and a 41% lower risk of all-cause death than metformin users, according to preliminary findings presented at the American Heart Association Scientific Sessions 2026. The study, drawing on TriNetX electronic health records from 104 institutions between 2010 and 2023, is among the largest to compare the two drug classes in the prediabetes population, a group that has received far less attention in GLP-1 research than patients with established type 2 diabetes.
The findings matter for the peptide therapy and research peptide industry because they push the clinical conversation upstream—toward earlier intervention in prediabetes—and because they arrive as demand for GLP-1 peptides continues to strain manufacturing, compounding and clinic capacity. For clinics, telehealth platforms and research-peptide suppliers, the data add a new layer to shared decision-making discussions with patients who are not yet diabetic but are seeking metabolic treatment. The analysis is observational and cannot establish cause and effect; its outcomes were identified through diagnosis codes, and prescription records did not capture adherence or dose.
What the 256,492-Patient Analysis Actually Found
The study compared adults with prediabetes and obesity who took a GLP-1-based medication—semaglutide, tirzepatide, liraglutide or dulaglutide—with those who took metformin. About half of the cohort was in each group, and the groups were matched on age, comorbidities such as high blood pressure and sleep apnea, and other medications. Patients averaged 52 years old, 76% were women, and follow-up averaged roughly three years.
According to the study authors, GLP-1 users had a 1.5 times higher chance of reverting to normal blood glucose levels than metformin users. They also had a 31% lower risk of developing type 2 diabetes and a 41% lower risk of death from any cause. Cardiovascular outcomes followed the same direction: 15% fewer heart attacks, 20% fewer strokes, 25% fewer heart failure cases and 8% fewer atrial fibrillation cases compared with metformin.
Vinicius de Sousa Barzon Serra, MD, a research fellow in cardiovascular medicine at Mayo Clinic in Scottsdale, Arizona, said the results may support considering GLP-1 medications earlier for certain patients rather than waiting until they develop type 2 diabetes. He also emphasized that metformin, along with lifestyle modification, remains the first-line medication for prediabetes and that the findings are less about replacing metformin than about discussing additional options.
Key Numbers at a Glance
| Measure | GLP-1 RA users vs metformin users |
|---|---|
| Reversion to normal blood glucose | 1.5 times higher chance |
| Risk of developing type 2 diabetes | 31% lower |
| Risk of all-cause death | 41% lower |
| Heart attacks | 15% fewer |
| Strokes | 20% fewer |
| Heart failure cases | 25% fewer |
| Atrial fibrillation cases | 8% fewer |
| Study population | 256,492 adults; mean age 52; 76% women; ~3-year follow-up |
Why This Matters for Peptide Therapy Clinics and Telehealth
Prediabetes is a large and growing market for metabolic services. Nearly 40% of U.S. adults have prediabetes, and up to 10% progress to type 2 diabetes each year, according to the AHA, citing its 2026 Heart Disease and Stroke Statistics and National Institutes of Health data. For peptide therapy clinics, medical spas and telemedicine platforms that already field requests for GLP-1 peptides, the new data may sharpen the case for structured screening and earlier conversations—while also raising questions about how to counsel patients who are not yet diabetic.
Industry observers note that the operational implications depend heavily on reimbursement and access. Robert Eckel, MD, FAHA, a past volunteer president of the AHA and a professor at the University of Colorado Anschutz Medical Campus who was not involved in the study, said the results were not surprising and likely reflect weight loss, which is known to help prevent type 2 diabetes. He noted that GLP-1s provide another option, perhaps as an add-on, and that costs and access are important factors.
For clinics, that cost-and-access caveat is not abstract. GLP-1 peptides are expensive, and insurance coverage for prediabetes remains inconsistent. A clinic that expands its prediabetes program may need to build cash-pay pathways, prior-authorization support and clear informed-consent language that distinguishes approved medicines from compounded or research-use-only products. This is where supply-chain transparency becomes a clinical issue, not just a procurement one.
Research and Market Context: STEP 10 and the Evidence Gap
The retrospective analysis echoes the phase 3 STEP 10 randomized trial, published in 2024 in The Lancet Diabetes & Endocrinology, in which 81% of adults with obesity and prediabetes receiving once-weekly semaglutide 2.4 mg reverted to normoglycemia at 52 weeks versus 14% of those receiving placebo. That trial compared semaglutide with placebo, not with metformin, so it does not directly answer the question the new observational analysis raises.
The distinction matters for how the industry communicates evidence. Randomized data support a normoglycemia-reversion signal for semaglutide against placebo; the new data suggest an association favoring GLP-1 receptor agonists over metformin, but the design cannot prove that the GLP-1 class caused the difference. Residual confounding, differences in adherence, and incomplete diagnosis coding are all plausible alternative explanations. The analysis also pooled semaglutide, tirzepatide, liraglutide and dulaglutide, so it does not assess whether individual agents differ.
For research-peptide suppliers and buyers, this evidence gap is familiar territory. A research-use-only peptide is not an approved medicine, and a certificate of analysis does not establish clinical safety or efficacy. The GLP-1 debate is a reminder that the same molecule name can refer to an approved drug, a compounded preparation or a research chemical—each with different regulatory status and quality expectations. Suppliers and clinic buyers increasingly need batch-level documentation, including HPLC and LC-MS data, to distinguish identity and purity from clinical claims.
Supply Chain and Manufacturing Implications
If the clinical conversation moves earlier into prediabetes, demand for GLP-1 peptides could broaden beyond the current base of patients with type 2 diabetes or obesity. That has implications for peptide API manufacturing, fill-finish capacity for vials and dual-chamber cartridges, and injection-pen supply. It also puts pressure on quality systems: as more clinics and telehealth operators enter the space, the ability to verify supplier documentation, traceability and batch consistency becomes a differentiator.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. It was compiled by David based on a news lead provided by Sarah, business manager at PeptideDDP, combined with publicly available information from the internet; the original information originates from PeptideDDP.com. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates. For operators tracking how GLP-1 demand moves through API sourcing, formulation and cross-border logistics, the practical question is not whether demand exists but whether supply chains can document what they are shipping.
Industry analysis suggests that clinics expanding prediabetes programs should treat supplier qualification as part of clinical risk management. That means confirming the exact peptide sequence or chemical identity, salt form, molecular weight, stated quantity, purity method and batch number before purchase, and verifying that the material is appropriate for its intended use. For research peptides, the research-use-only designation does not establish sterility, safety or authorization for human administration.
What Comes Next
The findings are preliminary and were presented at a scientific meeting; peer-reviewed publication and additional analyses may follow. Readers should watch for subgroup analyses by individual GLP-1 agent, by dose and adherence, and by duration of prediabetes. They should also watch for randomized or pragmatic trials that compare GLP-1 receptor agonists directly with metformin in prediabetes, since the current evidence base does not include such a head-to-head randomized comparison.
For now, metformin plus lifestyle modification remains the first-line approach for prediabetes. The new data may inform shared decision-making for certain patients, but they do not establish that GLP-1s should replace metformin, and they do not resolve questions about cost, access or long-term outcomes. Clinics, telehealth platforms and research-peptide businesses that communicate those limits clearly are likely to earn more trust than those that overstate the evidence.
Frequently Asked Questions
Did this study prove that GLP-1 drugs are better than metformin for prediabetes?
No. The analysis is observational and cannot establish cause and effect. It found associations, not proof, and the authors and independent experts emphasized that metformin remains first-line therapy.
How many people were in the study?
The retrospective analysis included 256,492 U.S. adults with prediabetes and obesity, using TriNetX electronic health records from 104 institutions between 2010 and 2023.
What did the STEP 10 trial show?
In the phase 3 STEP 10 trial, 81% of adults with obesity and prediabetes receiving once-weekly semaglutide 2.4 mg reverted to normoglycemia at 52 weeks versus 14% with placebo. The trial compared semaglutide with placebo, not metformin.
Are research peptides the same as approved GLP-1 medicines?
No. Research peptides are supplied for laboratory research and are not approved medicines. A research-use-only designation does not establish safety, sterility or authorization for human administration.
What should clinics verify before purchasing GLP-1 peptides?
Clinics should verify the exact sequence or chemical identity, salt form, molecular weight, quantity, purity method, batch number, storage requirements and supporting analytical documentation, and should confirm the regulatory status of the specific product.